(Q38038693)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22928901%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

title

Genomic variation-guided management in chronic hepatitis C (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22928901%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22928901%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Ching-Sheng Hsu

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22928901%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

publication date

1 August 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22928901%20AND%20SRC:MED&resulttype=core&format=json

Expert Review of Gastroenterology & Hepatology

12 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22928901%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22928901%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22928901%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

page(s)

497-506

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22928901%20AND%20SRC:MED&resulttype=core&format=json

Transmission of hepatitis C virus in Asia: past and present perspectives

12 February 2020

cites work

1 reference

Diagnosis, management, and treatment of hepatitis C

21 January 2018

1 reference

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

High diversity of hepatitis C viral quasispecies is associated with early virological response in patients undergoing antiviral therapy

21 January 2018

1 reference

Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholest

21 January 2018

1 reference

HCV core gene polymorphisms correlate with liver fibrosis but not sustained virological response in patients with genotype 1 infection.

21 January 2018

1 reference

Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection

21 January 2018

1 reference

Mutations in the NS5A and E2-PePHD regions of hepatitis C virus genotype 1b and response to combination therapy of interferon plus ribavirin

21 January 2018

1 reference

Mutations in the NS5B region of the hepatitis C virus genome correlate with clinical outcomes of interferon-alpha plus ribavirin combination therapy

21 January 2018

1 reference

Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan.

21 January 2018

1 reference

Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy

21 January 2018

1 reference

Predictors of response of US veterans to treatment for the hepatitis C virus

21 January 2018

1 reference

Association of lipid profiles with hepatitis C viral load in chronic hepatitis C patients with genotype 1 or 2 infection.

21 January 2018

1 reference

Associations between serum lipids and hepatitis C antiviral treatment efficacy

21 January 2018

1 reference

High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C.

21 January 2018

1 reference

Suppressor of cytokine signaling 3 (SOCS3) expression and hepatitis C virus-related chronic hepatitis: Insulin resistance and response to antiviral therapy

21 January 2018

1 reference

High hepatitis C viral load is associated with insulin resistance in patients with chronic hepatitis C.

21 January 2018

1 reference

Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis

21 January 2018

1 reference

The rate of fibrosis progression is an independent predictor of the response to antiviral therapy in chronic hepatitis C.

21 January 2018

1 reference

Hepatocyte steatosis is an important predictor of response to interferon (IFN) monotherapy in Japanese patients infected with HCV genotype 2a: Virological features of IFN-resistant cases with hepatocyte steatosis

21 January 2018

1 reference

The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients

21 January 2018

1 reference

Virus and host factors are both important determinants of response to interferon treatment among patients with chronic hepatitis C.

21 January 2018

1 reference

Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C.

21 January 2018

1 reference

IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C.

21 January 2018

1 reference

Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C.

21 January 2018

1 reference

Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C.

21 January 2018

1 reference

DNA polymorphisms and response to treatment in patients with chronic hepatitis C: results from the HALT-C trial

21 January 2018

1 reference

Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial

21 January 2018

1 reference

Interleukin 10 polymorphisms as predictors of sustained response in antiviral therapy for chronic hepatitis C infection

21 January 2018

1 reference

IL28B genomic-based treatment paradigms for patients with chronic hepatitis C infection: the future of personalized HCV therapies

21 January 2018

1 reference

Genetic variation in IL28B and spontaneous clearance of hepatitis C virus

21 January 2018

1 reference

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

21 January 2018

1 reference

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy

21 January 2018

1 reference

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

21 January 2018

1 reference

Interferon-alfa, interferon-lambda and hepatitis C.

21 January 2018

1 reference

Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy

21 January 2018

1 reference

ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C.

21 January 2018

1 reference

ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy--a genome-wide study of Japanese HCV virus patients.

21 January 2018

1 reference

Genome-wide association studies for complex traits: consensus, uncertainty and challenges

21 January 2018

1 reference

Understanding the host genetics of chronic hepatitis B and C.

21 January 2018

1 reference

Genes of the major histocompatibility complex class II influence the outcome of hepatitis C virus infection

21 January 2018

1 reference

Complete sequence and gene map of a human major histocompatibility complex. The MHC sequencing consortium

21 January 2018

1 reference

Cellular immune responses against hepatitis C virus

21 January 2018

1 reference

Immune responses during acute and chronic infection with hepatitis C virus

21 January 2018

1 reference

Influence of MHC class II genotype on outcome of infection with hepatitis C virus. The HENCORE group. Hepatitis C European Network for Cooperative Research

21 January 2018

1 reference

Association between HLA class II alleles and protection from or susceptibility to chronic hepatitis C.

21 January 2018

1 reference

Decreased frequency of the HLA-DRB1*11 allele in patients with chronic hepatitis C virus infection

21 January 2018

1 reference

Human leukocyte antigen class I and II alleles and response to interferon-alpha treatment, in Taiwanese patients with chronic hepatitis C virus infection

21 January 2018

1 reference

Distinct MHC class I and II alleles are associated with hepatitis C viral clearance, originating from a single source

21 January 2018

1 reference

HLA-Cw*04 and hepatitis C virus persistence

21 January 2018

1 reference

Protective effect of human leukocyte antigen B27 in hepatitis C virus infection requires the presence of a genotype-specific immunodominant CD8+ T-cell epitope

21 January 2018

1 reference

Viral evasion of natural killer cells

21 January 2018

1 reference

Natural killer cells and hepatitis C: action and reaction

21 January 2018

1 reference

HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection

21 January 2018

1 reference

Consistent beneficial effects of killer cell immunoglobulin-like receptor 2DL3 and group 1 human leukocyte antigen-C following exposure to hepatitis C virus

21 January 2018

1 reference

Interaction of NK inhibitory receptor genes with HLA-C and MHC class II alleles in Hepatitis C virus infection outcome

21 January 2018

1 reference

A polymorphism in IL28B distinguishes exposed, uninfected individuals from spontaneous resolvers of HCV infection.

21 January 2018

1 reference

Tumor necrosis factor- alpha promoter polymorphism at position -308 predicts response to combination therapy in hepatitis C virus infection

21 January 2018

1 reference

A functional SNP of interferon-gamma gene is important for interferon-alpha-induced and spontaneous recovery from hepatitis C virus infection

21 January 2018

1 reference

Large-scale candidate gene analysis of spontaneous clearance of hepatitis C virus

21 January 2018

1 reference

Polymorphisms in tumour necrosis factor-alpha, transforming growth factor-beta, interleukin-10, interleukin-6, interferon-gamma, and outcome of hepatitis C virus infection

21 January 2018

1 reference

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection

21 January 2018

1 reference

A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice

21 January 2018

1 reference

Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection

21 January 2018

1 reference

Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction

21 January 2018

1 reference

Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1.

21 January 2018

1 reference

Interferon-lambda serum levels in hepatitis C.

21 January 2018

1 reference

An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response

21 January 2018

1 reference

Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients

21 January 2018

1 reference

IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection

21 January 2018

1 reference

Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients

21 January 2018

1 reference

Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study

21 January 2018

1 reference

Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients.

21 January 2018

1 reference

Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C.

21 January 2018

1 reference

Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection

21 January 2018

1 reference

Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection

21 January 2018

1 reference

Telaprevir for previously treated chronic HCV infection

21 January 2018

1 reference

Boceprevir for previously treated chronic HCV genotype 1 infection

21 January 2018

1 reference

Boceprevir for untreated chronic HCV genotype 1 infection

21 January 2018

1 reference

Boceprevir for Chronic HCV Genotype 1 Infection

21 January 2018

1 reference

Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin.

21 January 2018

1 reference

Interferon lambdas: the next cytokine storm

21 January 2018

1 reference

Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection

21 January 2018

1 reference

Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics

21 January 2018

1 reference

21 January 2018

1 reference

Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-α-2a therapy

21 January 2018

1 reference